Scientific and Medical Expertise

Oncology Trial Imaging

Calyx’s scientific and medical experts have the industry’s most extensive experience in oncology trial imaging, having successfully managed the imaging components of over 1,600 clinical trials across 90 unique oncology indications, including over 75 trials of compounds that were designated breakthrough therapies.



Solid Tumor

Calyx’s scientific and medical experts have successfully managed the important imaging components of over 1,300 solid tumor trials – in all phases of clinical development across multiple indications such as cancer of the prostate, breast, bladder, and many more. You can trust Calyx to guide you through the highly nuanced and technically challenging world of clinical trial imaging to ensure your solid tumor development program succeeds. Or if it’s going to fail, to fail fast.



Calyx’s expert scientific and medical team is experienced in the successful implementation and operationalization of hematology trials, providing solutions to manage complex clinical data and advanced imaging. Our experience includes 300+ hematology trials, including support of 40+ approvals in Lymphoma, CLL, Waldenstorms and Multiple Myeloma.

You can trust the Calyx Medical Imaging team to provide reliable consultation on hematology trial design, template charters, and applications based on our lessons learned from previous studies incorporating reviewer, KOL, and regulatory feedback.

Learn how Calyx Medical Imaging provided the imaging services needed by a leading pharmaceutical company to support the primary efficacy endpoint of a multiple myeloma trial, delivering critical imaging data in advance of deadlines and helping the sponsor receive accelerated FDA approval.


Calyx provides a wide range of proven imaging services for Neuro-oncology clinical trials. Our network of scientific advisors and in-house expertise allows for full spectrum service offerings to help take your product from discovery to market.

Calyx’s experience in Neuro-oncology imaging includes:

— Primary or metastatic tumor detection/propagation on contrast-enhanced CT & MRI utilizing appropriate criteria and analysis approaches
— Superimposition of sequences to segment out tumor and edema volumes and follow over time
— Advanced MRI analysis per study needs


Calyx and Invicro merger to make a new global leader in medical imaging

Calyx and Invicro agree to combine to create a global leader in medical imaging and software solutions for the clinical research community

ILD toxicities that are caused by ADC-based oncology treatments, can be mitigated by using advanced medical imaging techniques like High-Resolution Computed Tomography

ADC-based Oncology Clinical Trials: Monitoring ILD Toxicities to Meet Regulators’ Expectations


De-risking Medical Imaging in Solid Tumor Trials

Multiparametric MR Imaging for Detection, Localization, and Staging of prostate cancer (PI-RADS)

Assessing Prostate Cancer Treatment Response Using PSMA PET/CT


Myeloma Trials: The Changing Landscape of Imaging in IMWG Response Assessment

Calyx supports Iovance groundbreaking Myeloma approval

Calyx Medical Imaging Supports Groundbreaking Melanoma Treatment Approval

Advancing the Science

Calyx employs some of the industry’s key thought leaders, including Dr. Oliver Bohnsack who wrote the book on medical imaging in oncology trials – literally. Dr. Bohnsack leverages his knowledge from having co-authored the immune-related response criteria (irRC, 2009), served as first author of irRECIST (2014), and co-authored Comparison of Assessments using RECIST and irRECIST by Manitz J. et al. (2020) as he designs and implements optimal imaging strategies for Calyx’s customers developing new oncology treatments.

Meet Our Scientists

    By submitting this form you consent to being contacted by Calyx for the purpose of responding to your inquiry.
    We respect your privacy and you can manage your communication preferences any time.
    You can find the Calyx privacy policy here.